Citations

Clear

4847 citation(s) found for "Tu, Eric".

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
Block, Matthew S. , Nelson, Garth D. , Chen, Jun , Johnson, Stephen , Yang, Lu , Flotte, Thomas J. , Grewal, Eric P. , McWilliams, Robert R. , Kottschade, Lisa A. , Domingo‐Musibay, Evidio , Montane, Heather N. , Hui, Jane Yuet Ching , Erskine, Courtney L. , Zahrieh, David , Flotte, Thomas James , Markovic, Svetomir , Dimou, Anastasios , Montane, Heather N , Piltin, Mara , Price, Daniel L , Khariwala, Samir S , Hui, Jane Yuet Ching , Erskine, Courtney L , Strand, Carrie A , Zahrieh, David , Dong, Haidong , Hieken, Tina J , McWilliams, Robert R , Chen, Jun , Grewal, Eric P , Johnson, Stephen , Markovic, Svetomir N. , Dimou, Anastasios , Piltin, Mara A. , Price, Daniel L. , Strand, Carrie , Dong, Haidong , Hieken, Tina J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | April 15, 2025 | Volume: 13 | Issue: 4 | Pages: e011706

10.1136/jitc-2025-011706 | PMID 40234093 Get It

Background Neoadjuvant treatment has become standard for patients with high-risk operable stage III melanoma, but the optimal regimen is unknown. Targeted therapy approaches yield high pathological response rates, while immunotherapy regimens show favorable recurrence-free survival (RFS). NeoACTIVATE was designed to address whether a neoadjuvant combination of both targeted therapy and immunotherapy might leverage the benefits of each. Methods We tested neoadjuvant treatment with 12 weeks of vemurafenib, cobimetinib, and atezolizumab for patients with BRAF-mutated (BRAFm) melanoma (cohort A) and cobimetinib and atezolizumab for patients with BRAF-wild-type (BRAFwt) melanoma (cohort B), regimens which we have shown generate a substantial major pathological response. After therapeutic lymph node dissection, patients received 24 weeks of adjuvant atezolizumab. Here, we report survival outcomes and their association with biomarkers assayed among the gut microbiome and peripheral blood immune subsets. Results With 49 months median follow-up, the median RFS was not reached for cohort A and was 40.8 months for cohort B. At 24 months after operation, 2 of 14 cohort A patients and 4 of 13 cohort B patients had experienced distant relapse. Key findings from correlative analyses included diversity, taxonomic and functional metagenomic gut microbiome signals associated with distant metastasis-free survival at 2 years. Notably, we observed a strong correlation between low microbial arginine biosynthesis (required for T-cell activation and effector function) and early distant recurrence (p=0.0005), which correlated with taxonomic differential abundance findings. Peripheral blood immune monitoring revealed increased double-positive (CD4+CD8+) T cells in patients with early recurrence. Conclusions Neoadjuvant treatment with cobimetinib and atezolizumab±vemurafenib was associated with a low rate of distant metastasis in patients with high-risk stage III melanoma. Freedom from early distant metastasis was highly associated with taxonomic differences in gut microbiome structure and with functional pathway alterations known to modulate T cell immunity. Identification of predictive biomarkers will permit optimization of neoadjuvant therapy regimens for individual patients. Trial registration number NCT03554083.
Surgical Recurrence Across Endoscopic Surgical Techniques in Idiopathic Subglottic Stenosis
Bowen, Andrew J. , Awadallah, Andrew S. , Ali, Hawa M. , McCalla, Monet, Roitman, Ariel , Leverson, Glen, Khalil, Yousuf H. , Ring, Sydney , Edell, Eric S. , Xie, Katherine , Francis, David O. , Dailey, Seth H. , Ekbom, Dale C. , Bowen, Andrew Jay , Ali, Hawa , Edell, Eric, Koster, Matthew, Xie, Katherine Z , Davis, Ruth , Francis, David O , Dailey, Seth H , Ekbom, Dale , Awadallah, Andrew , Bayan, Semirra L. , Koster, Matthew J.

Mayo Clinic

The Laryngoscope | April 15, 2025 | Volume: 135 | Issue: 9 | Pages: 3280-3286

10.1002/lary.32181 | PMID 40231755 Get It

ABSTRACTObjectiveWhile endoscopic laser wedge excision (LWE) for iSGS demonstrated lower surgical recurrence rates compared to endoscopic dilation (ED), ED remains the primary technique employed. Additionally, serial intralesional steroid injections (SILSIs) also demonstrate benefits in controlling disease. We aimed to compare surgical recurrence rates following ED, ED + SILSI, and LWE following a patient's first operation.MethodsThis was a two‐center retrospective analysis of iSGS patients who underwent either ED, ED + SILSI, or LWE. Patients were followed to their last follow‐up date or reoperation. Kaplan–Meier analysis and Cox proportional hazards were used to evaluate the recurrence times across the different surgical groups with additional stratification by age, compliance to medical adjuvant therapy, and percentage of stenosis rated at reoperation.ResultsA total of 126 patients from Institution 1 underwent LWE, while at Institution 2, ED and ED + SILSI were performed on 32 and 23 patients, respectively. One‐year recurrence estimates were 9%, 53%, and 0% for LWE, ED, and ED + SILSI, respectively, while 5‐year recurrence estimates were 45%, 90%, and 19%, respectively. Adjusted Cox‐proportional hazard ratios demonstrated a greater risk of surgical recurrence with ED compared to LWE (2.25; 95% confidence interval [CI]: 1.31–3.88) and no difference between ED + SILSI and LWE (0.84; 95% CI: 0.32–2.25).ConclusionLWE demonstrates reduced recurrence times compared to ED when controlling for surgery number, age, triple therapy compliance, and percentage of stenosis at reoperation. The application of postoperative SILSI appears to similarly reduce recurrence rates comparable to LWE and warrants further investigation.
National trends in prescription drug expenditures and projections for 2025
Tichy, Eric M. , Rim, Matthew H, Cuéllar, Sandra , Tadrous, Mina , Schumock, Glen T., Johnson, Thomas J., Newell, Mary Kate, Hoffman, James M.

Mayo Clinic

American Journal of Health-System Pharmacy | April 15, 2025 | Volume: 82 | Issue: 14 | Pages: 806-821

10.1093/ajhp/zxaf092 | PMID 40263109 Get It

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2025 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2025 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, endocrine drugs, generics, specialty drugs and vaccines. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2024 were made based on a combination of quantitative analyses and expert opinion. Results In 2024, overall pharmaceutical expenditures in the US grew 10.2% compared to 2023, for a total of $805.9 billion. Utilization (a 7.9% increase) and new drugs (a 2.5% increase) drove this increase, while prices remained flat (a 0.2% decrease). Semaglutide was the top drug in 2024, followed by tirzepatide and adalimumab. Drug expenditures were $39.0 billion (a 4.9% increase) and $158.2 billion (a 14.4% increase) in nonfederal hospitals and clinics, respectively. In clinics, increased utilization drove growth, with a small contribution from new products, while prices remained flat. In nonfederal hospitals, new products, price, and new volume each contributed modestly to growth in spend. Several new drugs that will influence spending are expected to be approved in 2025. Specialty, endocrine, and cancer drugs will continue to drive expenditures. Conclusion For 2025, we expect overall prescription drug spending to rise by 9.0 to 11.0%, whereas in clinics and hospitals we anticipate an 11.0% to 13.0% increase and a 2.0% to 4.0% increase, respectively, compared to 2024. These national estimates of future pharmaceutical expenditure growth may not be representative of any health system because of the myriad of local factors that influence actual spending.
Clinical significance of sleepiness: an American Academy of Sleep Medicine position statement
Heffron, Thomas M., Gurubhagavatula, Indira , Trotti, Lynn Marie , Abbasi-Feinberg, Fariha, Abreu, Alexandre Rocha, Bandyopadhyay, Anuja , Kuhlmann, David, Olson, Eric J. , Shelgikar, Anita V., Rowley, James A. , Trotti, Lynn Marie , Kapur, Vishesh K. , Martin, Jennifer L , Patil, Susheel P. , Wickwire, Emerson M.

Mayo Clinic

Journal of Clinical Sleep Medicine | April 14, 2025 | Volume: 21 | Issue: 6 | Pages: 1103-1107

10.5664/jcsm.11658 | PMID 40078104 Get It

Evaluation of an Automated Workstation for Aliquoting Whole Blood from Primary Sample Tubes
Zuckerman, Eric Zimmerman , Dukek, Brian A. , Hunsberger, Dee, Scheitz, Eric, Ward, A. H., Erickson, Steven, Hartman, Tom, Yiglletu, Martha, Baumann, N, Jannetto, Paul J. , Zimmerman Zuckerman, Eric , Dukek, Brian, Faber, Jennifer , Ward, Amanda, Baumann, Nikola, Jannetto, Paul, Faber, Jennifer, Ward, Amanda, Erickson, Steven, Hartman, Tom

Mayo Clinic

The Journal of Applied Laboratory Medicine | April 12, 2025 | Volume: 10 | Issue: 4 | Pages: 924-936

10.1093/jalm/jfaf035 | PMID 40219827 Get It

Abstract Background We evaluated the Tecan Fluent Mix and Pierce Workstation as an automated platform to aliquot directly from whole blood collection tubes. The Fluent Mix and Pierce Workstation uses the Tube Rotator™, an on-deck rotisserie, to keep whole blood in suspension, and 8 Piercing Tips™ to cross the pierceable caps of collection tubes to aliquot samples. Methods We performed accuracy and precision testing by aliquoting residual whole blood specimens into an on-deck gravimetric scale. To test carryover, we aliquoted alternating blanks and high calibrators for several analytes and performed mass spectrometry on the blanks. We performed 168 runs over a 21-day period to test the robustness of the platform. We aliquoted and analyzed 2 batches of samples on both our clinical platform and the Mix and Pierce Workstation to check concordance. Results We observed that the Fluent Mix and Pierce Workstation can aliquot 200 µL with 0.5% inaccuracy and 0.9%CV and can aliquot 300 µL with 0.1% inaccuracy and 0.7%CV. We were unable to detect any analyte carryover using mass spectrometry. We observed no hardware failures during the instrument stress test. Clinical comparison runs indicated that the performance of aliquots made on the Fluent Mix and Pierce Workstation was equivalent to that of aliquots made by our current clinical method. Conclusions Overall, our evaluation showed that the Tecan Fluent Mix and Pierce Workstation is a viable platform for aliquoting whole blood for downstream work flows and can eliminate labor-intensive sample decapping and recapping in high-throughput settings.
Standardizing the Definition of Each Colon Cancer Segment: Delphi Consensus on Clinical Decision-Making for Oncologic Outcomes
Kuzu, Mehmet Ayhan , Parvaiz, Amjad , Görgün, Emre , Wexner, Steven D. , Dozois, Eric J. , Hohenberger, Werner , Mišković, Danilo , Sugihara, Kenichi , Spinelli, Antonino , Wiggers, Theo , Basany, Eloy Espin, Uriburu, Juan C Patrón , Perez, Rodrigo Oliva , Lynch, Craig, Liu, Zheng , Chowdri, Nisar Ahmad , Madoff, Robert D. , West, Nick P, Şahin, Turgut , Bordeianou, Liliana , Group, On behalf of the Colon Cancer Delphi Consensus Study, Koh, Cherry , Perry, William , Park, Ji Won , Spinelli, Antonino , Wexner, Steven D , Perry, William R , Gaertner, Wolfgang B. , Benlice, Çiğdem , Bertelsen, Claus Anders , Lee, Woo-Yong , Möslein, Gabriela , Владимирович, Царьков Петр , Basany, Eloy Espin, Hahnloser, Dieter , Nilsson, Per Johan , Brown, Gina , Rouanet, Philippe , West, Nick P, Elhan, Atilla Halil , Group, On behalf of the Colon Cancer Delphi Consensus Study

Mayo Clinic

Diseases of the Colon & Rectum | April 11, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/dcr.0000000000003739 | PMID 40214091 Get It

BACKGROUND: Data registries lack a definitive classification system that distinguishes different locations of colon cancer from one another. OBJECTIVE: To establish an international consensus on the definition of primary colon cancer segment locations. DESIGN: Between December 2022 and June 2023, Delphi survey study was conducted to seek opinions from relevant international experts and eventually develop a consensus definition of each colon cancer segment. SETTING: Three-round online-based Delphi survey study. INTERVENTIONS: Online survey included 17 questions. In the first two rounds, participating experts were asked to rank each statement on a scale of 1–9 (9 is the most relevant). Consensus statements and definitions were revised according to results, obtaining a consensus score of 7–9. During the third round and online meeting, definitions and statements reached a moderate or high consensus(above 4 in more than 70% of participants) were included. MAIN OUTCOME AND MEASURE: Primary goal of our project was focused on precisely localizing the specific segment affected by primary colon cancer, rather than to identify surgical treatment or type of resection needed for particular segment. RESULTS: The first round included 331 experts, 301 (91%) completed the second round, and 295 (98%) completed the final round. Experts strongly supported the use of a “10 cm rule” to describe colon cancer sites at the flexures and anatomical landmarks for other segments. Regarding the definition of rectosigmoid cancer, experts from America and Europe reached a high consensus that the term rectosigmoid as a colon cancer location must be abolished in contrast to experts from Asia. Description of cancers overlapping segments achieved a consensus of 64%. LIMITATIONS: Subjective decisions are based on individual expert clinical experience. CONCLUSIONS: This Delphi survey, the first internationally conducted consensus study, achieved a remarkable level of consensus among a panel of global experts. Ambiguity still exists regarding overlapping lesions. See Video Abstract .
Pregnancy and Parity as Risk Factors for Recurrence in Idiopathic Subglottic Stenosis
Awadallah, Andrew S. , Fearington, Forrest W. , Khalil, Yousuf H. , Ali, Hawa M. , Li, Yan , Francis, David O. , Dailey, Seth H. , Edell, Eric S. , Ekbom, Dale C. , Bayan, Semirra L. , Awadallah, Andrew , Bowen, Andrew J. , Koster, Matthew J.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | April 11, 2025 | Volume: 173 | Issue: 2 | Pages: 447-452

10.1002/ohn.1255 | PMID 40211691 Get It

AbstractObjectiveThis study aims to evaluate the impact of parity on the severity and recurrence rates of idiopathic subglottic stenosis (iSGS) in premenopausal females.Study DesignA retrospective cohort study.SettingTwo tertiary care centers from 2002 to 2024.MethodsWe analyzed premenopausal iSGS patients under 40 years who underwent balloon dilation or laser wedge excision. Clinical features, including demographics and pregnancy history, were examined. Recurrence rates between nulliparous and parous patients were compared using Poisson regression, adjusting for age and follow‐up duration. Linear regression assessed the relationship between pregnancy and iSGS recurrence.ResultsForty‐eight patients were included, with 36 parous and 12 nulliparous. Adjusting for age and follow‐up, the mean recurrence rate was 2.6 times higher in parous patients (95% confidence interval [CI]: [1.5, 4.8], P = .0008). Each additional pregnancy was associated with 0.81 additional recurrences (95% CI: [0.05, 1.57], P = .0375). No significant differences in surgery‐free time were observed between groups.ConclusionParity and pregnancy significantly increase the risk of iSGS recurrence, although they do not accelerate subsequent recurrences. Health care providers should counsel women of childbearing age about these risks in family planning discussions, emphasizing shared decision‐making regarding potential surgical interventions.Level of evidence3.
Early increase of the synaptic blood marker β‐synuclein in asymptomatic autosomal dominant Alzheimer's disease
Day, Gregory S. , Huey, Edward D. , Xiong, Chengjie , Morris, John C., Roh, Jee Hoon , Otto, Markus , Network, the Dominantly Inherited Alzheimer, Otto, Markus , Day, Gregory S , Xiong, Chengjie , Roh, Jee Hoon , Oeckl, Patrick , Mayer, Benjamin , Bateman, Randall J. , Fox, Nick C. , Ibanez, Laura , Ikeuchi, Takeshi , Jucker, Mathias , Lee, Jae‐Hong , Llibre‐Guerra, Jorge J. , Lopera, Francisco Javier , McDade, Eric , Morris, John C., Niimi, Yoshiki , Sánchez‐Valle, Raquel , Schofield, Peter R. , Network, the Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | April 10, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.70146 | PMID 40207431 Get It

Abstract INTRODUCTION β‐synuclein is a promising blood marker to track synaptic degeneration in Alzheimer's disease (AD) but changes in preclinical AD are unclear. METHODS We investigated serum β‐synuclein in 69 cognitively unimpaired mutation non‐carriers, 78 cognitively unimpaired AD mutation carriers (asymptomatic AD), and 31 symptomatic mutation carriers from the Dominantly Inherited Alzheimer Network. RESULTS β‐synuclein levels were already higher in asymptomatic AD mutation carriers compared to non‐carriers and highest in symptomatic carriers. Longitudinal trajectories and correlation analyses indicated that β‐synuclein levels start to rise after amyloid deposition preceding axonal degeneration, brain atrophy and hypometabolism, and cognitive decline. β‐synuclein levels were associated with cognitive impairment and gradually increased with declining cognition. DISCUSSION Our study supports the use of blood β‐synuclein to track synaptic changes in preclinical AD and as a surrogate marker for cognitive impairment which might be used in early diagnosis and to support patient selection and monitoring of treatment effects in clinical trials. Highlights Blood β‐synuclein levels were already higher in asymptomatic Alzheimer's disease (AD) mutation carriers. Blood β‐synuclein levels were highest in symptomatic AD mutation carriers. Blood β‐synuclein levels start to rise 11 years before symptom onset. Rise of β‐synuclein precedes axonal degeneration, brain atrophy, and cognitive decline. β‐synuclein levels gradually increased with declining cognition.
Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Biermann, J. Sybil, Boles, Sarah G , Brigman, Brian E. , Callan, Alexandra K. , Cranmer, Lee D., Davis, Jessica , Donnelly, Eric D. , Ferguson, Michael J. , Graham, Ann, Groundland, John , Hess, Matthew, Hiniker, Susan M. , Hoover‐Regan, Margo , Jonard, Brandon , Lindskog, Dieter M. , Mayerson, Joel , McGarry, Sean V., Olson, Daniel J. , Rose, Peter S. , Santana, Victor M. , Satcher, Robert L. , Schwartz, Herbert S. , Shulman, Rebecca M. , Wustrack, Rosanna , Yoon, Janet, Hang, Lisa E., Jones, Frankie, Sansone, Nicholas, Lyons, Megan , Hirbe, Angela C. , Ahlawat, Shivani , Bernthal, Nicholas M , Binitie, Odion , Cipriano, Cara A. , Cranmer, Lee D. , Graham, Ann, Hess, Matthew, Hornick, Jason L. , Kuechle, Joseph , Morris, Carol D. , Thorpe, Steven W. , Wilky, Breelyn A , Lyons, Megan

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 9, 2025 | Volume: 23 | Issue: 4 | Pages: No page available

10.6004/jnccn.2025.0017 | PMID 40203873 Get It

Ewing sarcoma and osteosarcoma constitute 36% of all primary bone cancers. However, these 2 subtypes represent the most commonly diagnosed bone cancer types in the pediatric and adolescent population. Although still largely unknown, certain genetic mutations, rearrangements, and/or predisposition syndromes likely play a role in the pathogenesis of bone cancer. Osteosarcoma may also develop as a direct result of the long-term side effects of radiation therapy. With the implementation of a multimodality approach to treatment, including multiagent neoadjuvant and adjuvant chemotherapy regimens, targeted therapy options, surgery, and radiation, individuals with Ewing sarcoma and osteosarcoma are showing higher cure rates and improved overall survival. The NCCN Guidelines for Bone Cancer provide a consensus and evidence-based framework for the workup, management, and surveillance of local and recurrent/metastatic disease.